Asteria Health recalled 715 units of Estradiol, 37.5 mg pellets on January 26, 2026. The recall follows the potential presence of metal particulate matter in the product. Consumers should stop using the pellets immediately and contact their healthcare provider for further guidance.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Estradiol pellets are used in hormone replacement therapy for individuals experiencing menopause or other hormonal issues. Consumers typically purchase these pellets to manage symptoms associated with hormonal deficiencies.
The presence of metal particulate matter in the pellets can lead to serious health complications if ingested. This contamination poses an immediate risk to user safety.
This recall is not part of a broader industry pattern.
Consumers may face health risks due to potential metal contamination and should seek alternatives immediately.
The lot number can typically be found on the packaging or the product label.
Expect a refund process to take approximately 4-6 weeks after submitting your claim.
Keep a record of your purchase, any notifications received, and correspondence with the company for your records.
The recalled product is Estradiol, 37.5 mg, 1 Sterile Pellet, manufactured by Asteria Health. The lot number is 253000125, and the expiration date is June 9, 2026. The product was distributed nationwide in the USA.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Asteria Health recalled 133 estradiol pellets on January 26, 2026, after detecting potential metal particulate matter. The recall, classified as Class II, affects pellets with lot number 253000126 and an expiration date of June 9, 2026. Consumers must stop using the product immediately and contact their healthcare provider for guidance.
Asteria Health recalled 60,868 testosterone pellets on January 26, 2026, due to contamination risks. The recall affects specific lots of the product that may contain metal particulate matter. Consumers must stop using the product immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,015 testosterone pellets on January 26, 2026 due to potential metal particulate contamination. The recall affects products distributed nationwide in the United States. Consumers must stop using the pellets immediately and contact their healthcare provider for guidance.
Asteria Health recalled 89,074 testosterone pellets on January 26, 2026. The recall stems from potential metal particulate contamination. Consumers must stop using the product and contact their healthcare provider immediately.
Asteria Health recalled 22,478 Estradiol 12.5 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers and healthcare providers must stop using the product immediately. The FDA classified this recall as Class II, indicating a high hazard level.
Asteria Health recalled 24,099 Estradiol, 10 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers should stop using the product immediately. The recall affects pellets distributed nationwide in the USA.
Asteria Health recalled 50,990 Estradiol pellets on January 26, 2026, due to potential metal particulate matter contamination. The recall affects products distributed nationwide in the USA. Consumers should stop using the pellets immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,464 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. The recall affects products distributed nationwide. Consumers must stop using the product immediately and seek guidance from healthcare providers.